HUP0401910A2 - Novel use of substituted aminomethyl chromans and pharmaceutical compositions containing them - Google Patents
Novel use of substituted aminomethyl chromans and pharmaceutical compositions containing themInfo
- Publication number
- HUP0401910A2 HUP0401910A2 HU0401910A HUP0401910A HUP0401910A2 HU P0401910 A2 HUP0401910 A2 HU P0401910A2 HU 0401910 A HU0401910 A HU 0401910A HU P0401910 A HUP0401910 A HU P0401910A HU P0401910 A2 HUP0401910 A2 HU P0401910A2
- Authority
- HU
- Hungary
- Prior art keywords
- parkinsonism
- active ingredient
- parkinson
- disease
- combination
- Prior art date
Links
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 206010034010 Parkinsonism Diseases 0.000 abstract 7
- 208000027089 Parkinsonian disease Diseases 0.000 abstract 6
- 239000004480 active ingredient Substances 0.000 abstract 6
- 208000016285 Movement disease Diseases 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 3
- 208000018737 Parkinson disease Diseases 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- BSRHATGBRQMDRF-UHFFFAOYSA-N 3,4-dihydro-2h-chromen-2-ylmethanamine Chemical class C1=CC=C2OC(CN)CCC2=C1 BSRHATGBRQMDRF-UHFFFAOYSA-N 0.000 abstract 1
- 206010058504 Ballismus Diseases 0.000 abstract 1
- 206010008748 Chorea Diseases 0.000 abstract 1
- 206010009346 Clonus Diseases 0.000 abstract 1
- 229940123736 Decarboxylase inhibitor Drugs 0.000 abstract 1
- 208000012661 Dyskinesia Diseases 0.000 abstract 1
- 208000014094 Dystonic disease Diseases 0.000 abstract 1
- 208000027776 Extrapyramidal disease Diseases 0.000 abstract 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 abstract 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 abstract 1
- 208000005793 Restless legs syndrome Diseases 0.000 abstract 1
- 208000000323 Tourette Syndrome Diseases 0.000 abstract 1
- 208000016620 Tourette disease Diseases 0.000 abstract 1
- 206010044565 Tremor Diseases 0.000 abstract 1
- 208000018839 Wilson disease Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003954 decarboxylase inhibitor Substances 0.000 abstract 1
- 208000010118 dystonia Diseases 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
A találmány tárgya az (I) általános képletű helyettesítettaminometilkromán-származékok - a képletben R jelentése hidrogénatomvagy hidroxil védőcsoport, optikai izomerjeik és gyógyászatiszempontból elfogadható sóik vagy szolvátjaik alkalmazásaextrapiramidális mozgási rendellenességek, különösen idiopátiásParkinson-kórban alkalmazott parkinzonizmus ellenes hatóanyagokmellékhatásainak, idiopátiás Parkinson-kór, Parkinson-tünetegyüttesesetén alkalmazott parkinzonizmus ellenes hatóanyagok mellékhatásának,Parkinsontünetegyüttes, diszkinéziás és choreás tünetegyüttesek,disztóniás tünetegyüttesek, neuroleptikumok által kiváltottextrapiramidális tünetek, remegés, valamint a Gilles de la Tourette-tünetegyüttes, ballizmus, izomklónus, nyugtalanláb tünetegyüttes ésWilson-kór körébe tartozó extrapiramidális mozgási rendellenességekkezelésére szolgáló gyógyászati készítmény előállítására. A találmánytárgyát képezik továbbá a fenti hatóanyagot önmagában vagy szokásosparkinzonizmus ellenes hatóanyaggal kombinálva vagy szokásosparkinzonizmus ellenes hatóanyaggal és dekarboxiláz inhibitorralkombinálva tartalmazó gyógyászati készítmények, a fenti hatóanyagot ésparkinzonizmus ellenes hatóanyagot tartalmazó gyógyászati kombinációalkalmazása parkinzonizmus ellenes hatóanyagok hatásának fokozására,valamint az (I) általános képlet körébe tartozó (IA) képletűvegyületek és előállításuk. ÓThe subject of the invention is the use of substituted aminomethylchroman derivatives of the general formula (I) - in the formula R is a hydrogen atom or a hydroxyl protecting group, their optical isomers and their salts or solvates that are acceptable from a medical point of view, in the case of extrapyramidal movement disorders, especially the side effects of anti-parkinsonism agents used in idiopathic Parkinson's disease, idiopathic Parkinson's disease, Parkinson's symptom complex used for the production of a medicinal preparation for the treatment of the side effects of anti-parkinsonism active substances, Parkinson's syndrome, dyskinesia and chorea syndromes, dystonia syndromes, extrapyramidal symptoms induced by neuroleptics, tremors, and extrapyramidal movement disorders belonging to the Gilles de la Tourette syndrome, ballismus, muscle clonus, restless legs syndrome and Wilson's disease . The subject of the invention is also pharmaceutical preparations containing the above active ingredient alone or in combination with a conventional anti-parkinsonism active ingredient or in combination with a conventional anti-parkinsonism active ingredient and a decarboxylase inhibitor, the use of a medicinal combination containing the above active ingredient and an anti-parkinsonism active ingredient to enhance the effect of anti-parkinsonism active ingredients, as well as (IA) belonging to the general formula (I) ) compounds and their preparation. HE
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01122377 | 2001-09-19 | ||
| PCT/EP2002/009001 WO2003024960A1 (en) | 2001-09-19 | 2002-08-12 | Novel use of substituted aminomethyl chromans |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0401910A2 true HUP0401910A2 (en) | 2005-01-28 |
| HUP0401910A3 HUP0401910A3 (en) | 2011-02-28 |
Family
ID=8178662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0401910A HUP0401910A3 (en) | 2001-09-19 | 2002-08-12 | Novel use of substituted aminomethyl chromans and pharmaceutical compositions containing them |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7618988B2 (en) |
| EP (1) | EP1427724B1 (en) |
| JP (1) | JP4615857B2 (en) |
| KR (1) | KR100912911B1 (en) |
| CN (1) | CN100338060C (en) |
| AR (1) | AR036677A1 (en) |
| AT (1) | ATE325120T1 (en) |
| AU (1) | AU2002331229B2 (en) |
| BR (1) | BR0212555A (en) |
| CA (1) | CA2460696C (en) |
| CY (1) | CY1105118T1 (en) |
| DE (1) | DE60211186T2 (en) |
| DK (1) | DK1427724T3 (en) |
| ES (1) | ES2262840T3 (en) |
| HU (1) | HUP0401910A3 (en) |
| MX (1) | MXPA04002492A (en) |
| MY (1) | MY128882A (en) |
| PE (1) | PE20030428A1 (en) |
| PL (1) | PL208787B1 (en) |
| PT (1) | PT1427724E (en) |
| RU (1) | RU2322443C2 (en) |
| SI (1) | SI1427724T1 (en) |
| TW (1) | TWI244391B (en) |
| WO (1) | WO2003024960A1 (en) |
| ZA (1) | ZA200402855B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10318690B3 (en) * | 2003-04-24 | 2004-11-11 | Merck Patent Gmbh | Process for the preparation of nicotinaldehydes |
| FR2978916B1 (en) | 2011-08-10 | 2013-07-26 | Servier Lab | SOLID PHARMACEUTICAL COMPOSITION FOR BUCCAL ADMINISTRATION OF AGOMELATIN |
| NZ700474A (en) | 2012-04-18 | 2016-10-28 | Contera Pharma Aps | Orally available pharmaceutical formulation suitable for improved management of movement disorders |
| FR3001894A1 (en) | 2013-02-08 | 2014-08-15 | Servier Lab | SOLID PHARMACEUTICAL COMPOSITION FOR BUCCAL ADMINISTRATION OF AGOMELATIN |
| CN109689036A (en) | 2016-07-11 | 2019-04-26 | 康特拉医药公司 | For treating morning akinetic pulse delivery system |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5767132A (en) * | 1980-10-07 | 1982-04-23 | Nippon Steel Corp | Vertical type continuous annealing furnace having independently moving middle partition plate |
| DE4135474A1 (en) * | 1991-10-28 | 1993-04-29 | Bayer Ag | 2-AMINOMETHYL-chromans |
| SI9300097B (en) * | 1992-02-27 | 2001-12-31 | Janssen Pharmaceutica Nv | (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines |
| ES2212797T3 (en) * | 1993-08-19 | 2004-08-01 | Janssen Pharmaceutica N.V. | DERIVATIVES OF VASOCONSTRICTORS DIHYDROBENZOPIRAN. |
| DE69524528T2 (en) * | 1994-10-14 | 2002-08-01 | Merck Patent Gmbh | CNS active (R) - (-) - 2- [5- (4-fluorophenyl) -3-pyridylmethylaminomethyl] chroman |
| US5585388A (en) * | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| US5756521A (en) * | 1996-04-03 | 1998-05-26 | American Home Products Corporation | Chroman-2-ylmethylamino derivatives |
| UA73981C2 (en) * | 2000-03-10 | 2005-10-17 | Merck Patent Gmbh | (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit |
-
2002
- 2002-08-12 HU HU0401910A patent/HUP0401910A3/en unknown
- 2002-08-12 RU RU2004112190/15A patent/RU2322443C2/en not_active IP Right Cessation
- 2002-08-12 BR BR0212555-2A patent/BR0212555A/en not_active IP Right Cessation
- 2002-08-12 CA CA2460696A patent/CA2460696C/en not_active Expired - Fee Related
- 2002-08-12 EP EP02767363A patent/EP1427724B1/en not_active Expired - Lifetime
- 2002-08-12 AT AT02767363T patent/ATE325120T1/en active
- 2002-08-12 KR KR1020047002484A patent/KR100912911B1/en not_active IP Right Cessation
- 2002-08-12 WO PCT/EP2002/009001 patent/WO2003024960A1/en active IP Right Grant
- 2002-08-12 CN CNB028183266A patent/CN100338060C/en not_active Expired - Fee Related
- 2002-08-12 SI SI200230351T patent/SI1427724T1/en unknown
- 2002-08-12 MX MXPA04002492A patent/MXPA04002492A/en active IP Right Grant
- 2002-08-12 PL PL369684A patent/PL208787B1/en not_active IP Right Cessation
- 2002-08-12 AU AU2002331229A patent/AU2002331229B2/en not_active Ceased
- 2002-08-12 JP JP2003528807A patent/JP4615857B2/en not_active Expired - Fee Related
- 2002-08-12 PT PT02767363T patent/PT1427724E/en unknown
- 2002-08-12 DE DE60211186T patent/DE60211186T2/en not_active Expired - Lifetime
- 2002-08-12 ES ES02767363T patent/ES2262840T3/en not_active Expired - Lifetime
- 2002-08-12 US US10/489,960 patent/US7618988B2/en not_active Expired - Fee Related
- 2002-08-12 DK DK02767363T patent/DK1427724T3/en active
- 2002-08-13 TW TW091118183A patent/TWI244391B/en not_active IP Right Cessation
- 2002-09-16 MY MYPI20023438A patent/MY128882A/en unknown
- 2002-09-17 PE PE2002000915A patent/PE20030428A1/en not_active Application Discontinuation
- 2002-09-18 AR ARP020103509A patent/AR036677A1/en unknown
-
2004
- 2004-04-15 ZA ZA200402855A patent/ZA200402855B/en unknown
-
2006
- 2006-07-28 CY CY20061101061T patent/CY1105118T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200736223A (en) | N-(pyridin-2-yl)-sulfonamide derivatives | |
| ECSP034732A (en) | DERIVATIVE OF PHENETHANOLAMINE FOR THE TREATMENT OF RESPIRATORY DISEASES | |
| EA200800056A1 (en) | CANNABINOID ACTIVE PHARMACEUTICAL INGREDIENT FOR MEDICINAL FORMS | |
| UA92181C2 (en) | New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimers disease | |
| BR0214343A (en) | 11 - Beta - Hydroxy Steroid Dehydrogenase Inhibitors Type 1 | |
| SE0001899D0 (en) | New compounds | |
| NO20051962L (en) | Phenethanolamine derivatives for the treatment of respiratory diseases | |
| AR035792A1 (en) | COMPOUNDS OF N- (4-QUINAZOLINIL) -N- (1H-INDAZOL-5-IL) AMINA, INHIBITOR OF RHO-KINASE, ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND METHOD TO PREPARE IT | |
| MXPA04004837A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1. | |
| MXPA04004842A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1. | |
| KR20220056256A (en) | Compositions and methods for managing or improving bone disorders, cartilage disorders, or both | |
| TW200633978A (en) | 2,3,4,9-tetrahydro-1H-carbazole derivatives as crth2 receptor antagonists | |
| BRPI0417833A (en) | benzofuran derivatives which may be used for the prophylaxis or treatment of 5-ht6 receptor-related disorders | |
| ES2193875A1 (en) | Benzoxazinone derivatives, the preparation and use thereof as medicaments | |
| WO2006115770A3 (en) | Orally disintegrating pharmaceutical tablet formulations of olanzapine | |
| UA84896C2 (en) | Hydronopol derivatives as agonists on human orl1 receptors | |
| RS44204A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| HUP0400386A2 (en) | Tablet comprising cetirizine and pseudoephedrine and its use for preparation of pharmaceutical compositions | |
| HUP0303450A2 (en) | Method to prepare microparticles containing metoprolol and pharmaceutical compositions containing them | |
| IT1265340B1 (en) | SUBSTANCES INHIBITING PROTEIN ADP-RIBOSYLATION SUITABLE FOR THE PREVENTION OF COMPLICATIONS OF DIABETES MELLITUS. | |
| HUP0401910A2 (en) | Novel use of substituted aminomethyl chromans and pharmaceutical compositions containing them | |
| KR102254542B1 (en) | Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders | |
| RS44304A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| DE602004019500D1 (en) | 4-substituirte-5-cyano-1h-pyrimidin-6-(th)iones als als gsk-3-hemmer | |
| HUP0402093A2 (en) | 3-phenyl-2-phenethylthio-propionic acid derivatives as selective agonists of ppar-alpha, their preparation and pharmaceutical compositions containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |